Patent Classification

1. Ketosis-treating agent

1. Compositions and methods for the treatment of viral disorders
    
2. Spliced gene of KSHV / HHV8, its promoter and monoclonal antibodies specific for LANA2
    
3. Treatment of Kaposi's sarcoma with IL-12
    
4. Treatment of Kaposi's sarcoma with IL-12
    
5. Genes of kaposi's sarcoma associated herpesvirus

1. In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    
2. In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    
3. Measurement of renal extraction fraction using contrast enhanced computed tomography
    
4. Process for metabolic control and high solute clearance and solutions for use therein
    
5. Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma
    
6. ILK inhibitors for the treatment of renal disease
    
7. Co-administration of cG250 and IL-2 or IFN-.alpha. for treating cancer such as renal cell carcinomas
    
8. Method for mitigating injury to a kidney resulting from an ischemic event
    
9. Reagent sets and gene signatures for renal tubule injury
    
10. Enteric coated oral pharmaceutical to erode kidney stones
     
11. Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
     
12. Method of expressing foreign gene in kidney
     
13. Induction of tubular morphogenesis using pleiotrophin
     
14. Methods for identification of alport syndrome
     
15. Use of treprostinil to improve kidney functions
     
16. Systems and methods related to degradation of uremic toxins
     
17. Use of rare earth compounds for the prevention of kidney stone disease
     
18. Methods of detecting early renal disease in animals
     
19. Preventives and/or remedies for hyperphosphatemia
     
20. Method of forming vascularized kidney tissue
     
21. Composition and method for improving function of embryonic kidney transplants
     
22. Oral bacteriotherapy compositions and methods
     
23. Biochemically balanced peritoneal dialysis solutions
     
24. Method and composition for supplementation of nutritional deficiencies in renal patients
     
25. Methods and compositions for treating nephrotic syndrome
     
26. Method for diagnosing nephropathy
     
27. Diagnosis and treatment of human kidney diseases
     
28. Antisense to c-myc for treatment of polycystic kidney disease
     
29. Therapeutic agents for glomerulosclerosis
     
30. Methods for functional kidney imaging using small dendrimer contrast agents
     
31. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
     
32. Use of urodilatin for treating chronic kidney failure with residual kidney functions
     
33. System for treating kidney disease in diabetic and non-diabetic patients
     
34. Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use
     
35. Method of use of erythropoietin to treat ischemic acute renal failure
     
36. Substitution infusion fluid and citrate anticoagulation
     
37. Composition for alleviating symptoms of uremia in patients
     
38. Renal cell carcinoma treatment
     
39. Method of treating BK virus nephropathy
     
40. Method for treating renal disease, and pharmaceutical composition for treating renal disease
     
41. Treatment of renal disorders
     
42. Morphogen treatment for chronic renal failure
     
43. Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
    
    
44. Method for preventing and/or treating renal disease
     
45. Kidney injury-related molecules
     
46. Methods for the treatment of nephro-disorders using aminothiol compounds
     
47. Gene encoding organic anion transporter
     
48. Method of administration of a nutritional product to a person having renal failure
     
    
49. Methods and composition for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells

1. Augmented cognitive training
    
2. Gene functionally related to dyslexia
    
3. Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
    
4. Gene functionally related to dyslexia
    
5. Method of treating a cognitive memory dysfunction using Gugulipid
    
6. Method for assessing the effect of a drug on long term memory formation
    
7. Neuroceutical for improving memory and cognitive abilities
    
8. Memory loss treatment formulation
    
9. Learning and short term memory defects with Neurofibromatosis 1 (NF1) expression

1. Control of protozoa and protozoan cysts that harbor legionella

1. Polypeptides of Leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
    
2. Process for the in vitro culture of different stages of tissular parasites
    
3. Method of treating leishmaniasis using methyl-beta-cyclodextrin
    
4. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
    
5. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
    
6. Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
    
7. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained

1. Leptospira vaccine antigens for the prevention of Leptospirosis
    
2. Leptospira vaccine antigens for the prevention of Leptospirosis

1. Methods for phenotyping of leukemias
    
2. Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    
3. Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
    
4. Methods to impair hematologic cancer progenitor cells and compounds related thereto
    
5. Needle-free administration of FeLV vaccines
    
6. Antitumoral treatments
    
7. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
    
8. Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof
    
9. Anti-CD20 antibodies and fusion proteins thereof and methods of use
    
10. Chronic lymphocytic leukemia cell line
     
11. Vaccines for treatment of lymphoma and leukemia
     
12. Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
     
13. Compositions and method for WT1 specific immunotherapy
     
14. Immunotherapy for chronic myelocytic leukemia
     
15. CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
     
16. Strategy for leukemia therapy
     
17. Early leukemia diagnostics using microsphere arrays
     
18. Ex vivo generation of functional leukemia cells in a three-dimensional bioreactor
     
19. Method for treating diseases associated with abnormal kinase activity
     
20. Depletion method of blood plasma ascorbate
     
21. Treatment of chronic myelogenous leukemia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
     
22. Herbal-based composition for treating acute and chronic myeloid leukemia
     
23. Method of modulating tumor immunity
     
24. Method of cancer treatment
     
25. Method of treating leukopenia with adenosine
     
26. Antibodies for judging possibility of the onset of bovine leukemia
     
27. Chronic lymphocytic leukemia treatment
     
28. Process for preparation of a biomarker specific for O-acetylated sialic acid useful for diagnosing, monitoring treatment outcome, and predicting relapse of lymphoblastic leukemia
     
29. Methods for diagnosing and evaluating cancer
     
30. Variant tax gene of bovine leukemia virus
     
31. Antibodies that bind the cytokine designated LERK-5
     
32. Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cell
     
33. Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
     
34. Purging leukemia cells from hematopoietic stem cells
     
35. Serum-derived factor inducing cell differentiation and medical uses thereof
    
    
36. CML Therapy
    
    
37. Combination therapy for lymphoproliferative diseases
     
38. Method of inducing apoptosis in cancer cells using an extract of Melothria indica Lou

1. Role of p62 in aging-related disease
    
2. Composition and method for treating age-related disorders
    
3. Method of determining biological/molecular age
    
4. Interventions to mimic the effects of calorie restriction

1. 18891, a novel human lipase

1. Chromosome 3p21.3 genes are tumor suppressors
    
2. Method of classifying gene expression strength in lung cancer tissues
    
3. Targeting of Notch3 receptor function for cancer therapy
    
4. Marker molecules associated with lung tumors
    
5. Molecular characteristics of non-small cell lung cancer
    
6. Rapid efficacy assessment method for lung cancer therapy
    
7. Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
    
8. Non-human animal exhibiting bone metastasis of tumor cells
    
9. Molecular characteristics of non-small cell lung cancer
    
10. Aerosol drug inhibition of lung metastases
     
11. Nucleic acid mutation detection by analysis of saliva
     
12. Gene markers for lung cancer
     
13. Detection and treatment of cancers of the lung
     
14. Method of diagnosing, monitoring, and staging lung cancer
     
15. Biological compositions and methods for treatment of lung cancer
     
16. Compositions and methods for the therapy and diagnosis of lung cancer
     
17. Compounds and methods for therapy and diagnosis of lung cancer
     
18. Compounds and methods for therapy and diagnosis of lung cancer
     
19. Compounds and methods for therapy and diagnosis of lung cancer

1. Diagnosis and monitoring of systemic lupus erythematosus and of scleroderma
    
2. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
    
3. IL-16 antagonists
    
4. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
    
5. Treatment of lupus erythematosus

1. VMP-like sequences of pathogenic Borrelia species and strains
    
2. Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi
    
3. Recombinant constructs of Borrelia burgdorferi
    
4. Lyme disease vaccines
    
5. Vmp-like sequences of pathogenic Borrelia
    
6. Test for lyme disease
    
7. Prevention, diagnosis and treatment of lyme disease
    
8. Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
    
9. Method for treatment of lyme disease
    
10. Immunologically active proteins from Borrelia burgdorferi
     
11. VMP-like sequences of pathogenic borrelia
     
12. Compositions and methods comprising DNA sequences encoding B. burgdorferi polypeptides

1. Method for the treatment of lymphedema using guaifenesin

1. Controlled release nanoparticle having bound oligonucleotide for targeted delivery
    
2. Antitumoral treatments
    
3. Anti-CD20 antibodies and fusion proteins thereof and methods of use
    
4. Vaccines for treatment of lymphoma and leukemia
    
5. Compositions and methods for treatment of non-Hodgkin's lymphoma
    
6. Method for limiting the growth of cancer cells using an attenuated measles virus
    
7. Ctage gene family
    
8. Compositions, methods and kits for diagnosis and treatment of Chlamydia pneumoniae infections of the skin and those associated with cutaneous T-cell lymphoma
    
9. Animal model of human hematopoietic tumor
    
10. Compositions and methods for treating lymphoma
     
11. Methods for treatment of cutaneous T-cell lymphoma
     
12. Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
     
13. Method of modulating tumor immunity
     
14. Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
     
15. Methods for treating b cell lymphoma using CD80-specific antibodies
     
16. Compositions and methods for treating lymphoma
     
17. Lymphoma-susceptible transgenic mice and methods for studying drug sensitivity of lymphomas

1. Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
    
2. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
    
3. Methods of treating lysosomal storage diseases

1. Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
    
2. Malaria vaccines
    
3. Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
    
4. Method of producing partial peptide of enolase protein from Plasmodium falciparum
    
5. Methods for the formulation and manufacture of artesunic acid for injection
    
6. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
    
7. Malaria vaccines
    
8. Recombinant P. falciparum merozoite protein-1.sub.42 vaccine
    
9. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
    
10. Recombinant viral-based malaria vaccines
     
11. Vaccines for blocking transmission of plasmodium vivax
     
12. Recombinant viral-based malaria vaccines
     
13. Compositions and methods for treating malaria with cupredoxin and cytochrome
     
14. Membrane virus host range mutations and their uses as vaccine substrates
     
15. Live genetically attenuated malaria vaccine
     
16. Recombinant P. falciparum merozoite protein-1.sub.42 vaccine
     
17. Compositions and methods for the generation of protective immune responses against malaria
     
18. Malaria polypeptides
     
19. Live genetically attenuated malaria vaccine
     
20. Artemisinins with improved stability and bioavailability for therapeutic drug development and application
     
21. Synthetic genes for malarial proteins and methods of use
     
22. Isolation, characterization, cloning and use of a mushroom lectin
     
23. Artemisinins with improved stability and bioavailability for therapeutic drug development and application
     
24. Malaria immunogen and vaccine
     
25. Pharmacological targeting of mRNA cap formation for treatment of parasitic infections
     
26. Recombinant multivalent malarial vaccine against Plasmodium falciparum
     
27. Transmission blocking immunogen from malaria
     
28. Malaria immunogenic composition
     
29. Modified MSP-1 nucleic acid sequences and methods for increasing MRNA levels and protein expression in cell systems
     
30. Malaria vaccine
     
31. Polypeptides and DNA encoding same
     
32. Malaria merozoite antigen subunit vaccine
     
33. Combination preparation for treating malaria

1. Infectious recombinant paramyxovirus from antigenomic cDNA
    
2. Naturally processed measles virus peptides eluted from class II HLA molecules
    
3. Method for producing temperature-sensitive morbillivirus
    
4. Gene coding for the measles virus mutant antigen

1. Surface antigen
    
2. Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
    
3. Polynucleotides and polypeptides BASB033 from Neisseria meningitidis and their uses
   
 
4. Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
    
5. Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis
    
6. Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
    
7. Monoclonal antibody to the stabilizer peptide of the P64K antigen of Neisseria meningitidis
    
8. Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
    
9. Multicomponent meningococcal vaccine
    
10. Neisseria meningitidis antigen
     
11. Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
     
12. Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
     
13. Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses
     
14. Therapeutic uses of BPI protein products for human meningococcemia
     
15. Invasion associated genes from Neisseria meningitidis serogroup B
     
16. Methods of immunizing adults using anti-meningococcal vaccine compositions
     
17. Antibodies to meningococcal polysaccharide conjugate vaccines

1. Composition for treatment of menopause
    
2. Methods and devices for the sustained release of multiple drugs
    
3. Composition for treatment of menopause
    
4. Treatment of conditions relating to hormone deficiencies by administration of progestins
    
5. Menopause disorder synergistic phyto-nutraceutical composition
    
6. Herbal supplement for cognitive related impairment due to estrogen loss
    
7. Protection of the female reproductive system from natural and artificial insults
    
8. Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
    
9. Anti-aging/menopause symptoms relief using ganoderma lucidum spores
    
10. Hormonal composition consisting of an oestrogen compound and of a progestational compound
     
11. Low dose estrogen interrupted hormone replacement therapy
     
12. Methods of diagnosing early-onset menopause
     
13. Methods for treating postmenopausal women using ultra-low doses of estrogen
     
14. Ovariectomized mouse model for human menopause
     
15. Method for the treatment of symptoms related to normal hormonal variations in women
     
16. Formulation for menopausal women
     
17. Herbal supplement for cognitive related impairment due to estrogen loss

1. Treatment of premenstrual disorders
    
2. Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
    
3. Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product

1. Methods of treating lysosomal storage related diseases by gene therapy
    
2. Methods of treating Syndrome X with aliphatic polyamines
    
3. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    
4. Methods for treating a patient having Metabolic Syndrome
    
5. Process for the preparation of amylase inhibitor
    
6. Compositions and methods for treatment for glucose metabolism disorders
    
7. Method for treating a patient having metabolic syndrome
    
8. High throughput screening assays using fatty acid synthetic enzymes
    
9. Acceleration of the rate of digestion of a protein
    
10. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
     
11. Method of preventing development of severe metabolic derangement in inborn errors of metabolism

1. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
    
2. Migraine and vasodilation treatment
    
3. Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
    
4. Intravenous valproate for acute treatment of migraine headache
    
5. Delivery of compounds for the treatment of migraine through an inhalation route
    
6. Delivery of compounds for the treatment of migraine through an inhalation route
    
7. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
    
8. Formulations and methods for treating chronic migraine
    
9. Treatment of migraine headache
    
10. Composition for the treatment of migraine
     
11. Use of valproic acid analog for the treatment and prevention of migraine and affective illness

1. Anti-depressant, stress suppressor and mood improver
   
   
2. Composition for controlling mood disorders in healthy individuals

1. Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
    
2. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
    
3. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity

1. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
    
2. Therapeutic composition for the prevention and treatment of mucositis and mucosal disorders
    
3. Method of using IL-11 for treating mucositis
    
4. Compositions and methods for the treatment or prevention of inflammation
    
5. Methods and compositions for treating pain of the mucous membrane
    
6. Methods and compositions for treating and preventing mucositis

1. Monoclonal antibodies to progastrin
    
2. Modulation of toll-like receptor 5 expression by antisense oligonucleotides
    
3. Method of treating or preventing a disease or condition mediated by pathogenic IgG antibodies
    
4. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
    
5. Methods of inhibiting T1R1/T1R3 heteromeric umami taste receptors
    
6. Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
    
7. Antibodies which bind specifically to activin receptor like kinase 3
    
8. Investigation of mucosa dryness conditions
    
9. Recombinant transferrins, transferrin half-molecules and mutants thereof
    
10. Methods for treatment of nocturia
     
11. Anti-myostatin antibodies
     
12. Human luteinizing hormone superagonists
     
13. Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
     
14. Human N-type calcium channel isoform and uses thereof
     
15. Targeted iron chelator delivery system
     
16. Anti-CD26 antibodies and methods of use thereof
     
17. Method for increasing plasma volume by administering a plasma expander comprising basic alpha keratose
     
18. Prodrug of an ICE inhibitor
     
19. Bioinformatic approach to disease diagnosis
     
20. Use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium
     
21. Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
     
22. Gut commensal bacterium and methods of using the same
     
23. Antibodies to insulin-like growth factor I receptor
     
24. Insulin-like growth factor antibodies and uses thereof
     
25. Method and apparatus for uterus stabilization
     
26. Compounds and compositions as hedgehog signaling pathway modulators
     
27. .beta.-like glycoprotein hormone polypeptide and heterodimer
     
28. Signatures for human aging
     
29. Method for monitoring the efficacy of a Mycobacterium avium subspecies paratuberculosis therapy
     
30. Method and material for enhanced tissue-biomaterial integration
     
31. Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
     
32. Post-translational modifications and Clostridial neurotoxins
     
33. Extended release formulation and method of treating adrenergic dysregulation
     
34. Characterization of granulocytic Ehrlichia and methods of use
     
35. Intracorporeal medicaments for photodynamic treatment of disease
     
36. PDE11A mutations in adrenal disease
     
37. Regulation of kinase, regulated in COPD kinase (RC kinase)
     
38. Product and method for treatment of conditions associated with receptor-desensitization
     
39. Methods for enhancing therapeutic effects of a neurotoxin
     
40. Drug delivery system targeting to estrogen receptor over-expressed cells
     
41. Gene functionally related to dyslexia
     
42. Pharmaceutical compositions and methods for peptide treatment
     
43. Lipophilic diesters of chelating agent for inhibition of enzyme activity
     
44. Antibodies to Dkk-1
     
45. Therapeutic use of anti-CS1 antibodies
     
46. Antibodies to insulin-like growth factor I receptor
     
47. Carbon monoxide as a biomarker and therapeutic agent
     
48. Use of IL-18 inhibitors for treating head injuries
     
49. Preventing transfusion related complications in a recipient of a blood transfusion
     
50. Chemical induced intracellular hyperthermia
     
51. Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1
     
52. Antibodies which bind specifically to activin receptor like kinases
     
53. Antibodies to M-CSF
     
54. Mutant having uracil phosphoribosyl transferase activity
     
55. Method for assessing the effect of a drug on long term memory formation
     
56. Binding compounds specific for cysteine-rich soluble protein C23
     
57. Compositions and methods for delivery of caffeine
     
58. Polynucleotide therapy
     
59. Small and intermediate conductance, calcium-activated potassium channels and uses thereof
     
60. Gene regulation therapy involving ferritin
     
61. Treatment of diseases involving defective gap junctional communication
     
62. Metalloproteinase-binding proteins
     
63. Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
     
64. Therapy of diseases of the eye, the inner ear and the central nervous system
     
65. Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract
     
66. Adenosine receptor
     
67. Fibroblast growth factor-like polypeptides
     
68. Methods and composition for modulating and detecting wisp activity
     
69. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
     
70. Combination therapy for treating protein deficiencies
     
71. High-affinity choline transporter
     
72. Proteins within the type E botulinum neurotoxin complex
     
73. Heat shock protein-based vaccines and immunotherapies
     
74. Treatment of complement-associated disorders
     
75. Methods of inhibiting ectopic calcification
     
76. Tissue-specific transporter inhibitor
     
77. Human checkpoint kinase, hCDS1, compositions and methods
     
78. hKIS composition and methods of use
     
79. Monoclonal blocking antibody to human RANKL
     
80. Treatment of IgA1 deposition diseases
     
81. Treatment of disease by inducing cell apoptosis
     
82. Heparin prodrugs and drug delivery stents formed therefrom
     
83. Leucine-based motif and Clostridial neurotoxins
     
84. Intracorporeal medicaments for photodynamic treatment of disease
     
85. NF-.kappa.B peptides designed to disrupt NEMO oligomerization
     
86. Methods for preparing low molecular weight heparin with modified heparinase III
     
87. Methods and compositions for regulating imidazoline receptors
     
88. Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
     
89. Rehydration composition
     
90. Method for treating disorders and diseases treatable with human fibroblast interferon
     
91. Polypeptides of the IFN.alpha.-5 gene
     
92. Treatment of Pompe's disease
     
93. Use of an agent that restores tissue perfusion and oxygenation
     
94. Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
     
95. Q3 SPARC deletion mutant and uses thereof
     
96. Antibody to human enzymes of the metalloprotease family
     
97. Method for nonsurgical treatment of the intervertebral disc and kit therefor
     
98. Antibodies against gene products related to Werner's Syndrome
     
99. Nitric oxide-producing hydrogel materials
     
100. Designing compounds specifically inhibiting ribonucleic acid function
      
101. Lipid emulsions in the treatment of systemic poisoning
      
102. Human high affinity choline transporter
      
103. Interferon alpha responsive protein
      
104. Microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities
      
105. Black tea extract for prevention of disease
      
106. IL-16 antagonists
      
107. Oxygenated albumin for use as blood and blood extender
      
108. Orally-administered interferon-tau compositions and methods
      
109. Compositions for the relief of xerostomia and the treatment of associated disorders
      
110. Variant B7 co-stimulatory molecules
      
111. 150 KDA TGF-B1 accessory receptor acts a negative modulator of TGF-B signaling
      
112. Scorpion toxins
      
113. Antibody to GALP and uses thereof
      
114. Method to identify regulators of cellular activation using Bcl10
      
115. V-like domain binding molecules
      
116. Histamine receptor antibody
      
117. RANTES mutants and therapeutic applications thereof
      
118. Specific binding members for TGF.beta..sub.1
      
119. Compositions relating to novel compounds and targets thereof
      
120. Lipoxygenase proteins and polynucleotides encoding the same
      
121. Compositions for preventing hormone induced adverse effects
      
122. Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
      
123. Method of treating graft versus host disease by administration of a Fas antagonist
      
124. Secreted and transmembrane polypeptides and nucleic acids encoding the same
      
125. Caspase 9 activation and uses therefor
      
126. Compositions and methods for an orally administered inhibitor of biting insects
      
127. cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
      
128. Antibodies to human chemokine beta-9
      
129. Human TIMP-1 antibodies
      
130. Methods for treating early morning pathologies
      
131. Epidermal growth factor agonists
      
132. Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
      
133. .alpha.-Glucosidase inhibitors from a natural source
      
134. Follicle stimulating hormone superagonists
      
135. Human methionine synthase reductase: cloning, and methods for evaluating risk of, preventing, or treating neural tube defects, cardiovascular disease, cancer, and down's syndrome
      
136. Human voltage gated sodium channel .beta.1A subunit and methods of use
      
137. Monoclonal antibody specific for advanced glycosylation endproducts in biological samples
      
138. Swallowing-assistive drink
      
139. Peptides and nucleic acids derived from Eisenia foetida and the use thereof
      
140. Mineral absorption enhancer
      
141. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
      
142. Antibodies against human IL-12
      
143. Guanosine monophosphate reductase
      
144. IL-16 antagonists
      
145. Neurturin antibody
      
146. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
      
147. Method for treating mammals with modified mammalian blood
      
148. Method for treating a mucus secretion
      
149. Calcium channel proteins
      
150. Paroxetine controlled release compositions
      
151. Microtubule-associated proteins and tubulins
      
152. Human phospholipase C delta 5
      
153. Urocortin-III and uses thereof
      
154. G-CSF analog compositions and methods
      
155. Prostate associated Ets protein
      
156. Methods for preparing pharmaceutical formulations
      
157. Methods of using antibodies to human receptor protein 4-1BB
      
158. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
      
159. Methods for activating natural killer (NK) cells and means for carrying out said methods
      
160. Regulatory/unfolding peptides of ezrin
      
161. Peptides
      
162. Diagnosis and treatment of PTP04 related disorders
      
163. Method for removing the transforming growth factor-.beta. by adsorption
      
164. Crosslinked gelatin gel preparation containing basic fibroblast growth factor
      
165. Truncated CRAF1 inhibits CD40 signaling
      
166. Compositions and methods for treating or preventing diseases of body passageways
      
167. Method of modulating neovascularization
      
168. Mutual prodrug of amlodipine and atorvastatin
      
169. Method of using fermented glycine max (L) extract for enhancing natural killer cell activity
      
170. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
      
171. Recombinant anti-CCR2 antibodies and methods of use therefor
      
172. Methods for determining toxicity reversing agents
      
173. Compositions and methods for identifying antigens which elicit an immune response
      
174. Treatment of substance P-related disorders
      
175. Proteins within the type E botulinum neurotoxin complex
      
176. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
      
177. Systemic immune activation method using nucleic acid-lipid complexes
      
178. Peptide Compositions which induce immune tolerance and methods of use
      
179. Human galactosyltranferases
      
180. Method of blocking blood vessel growth using tie-2 ligand 2
      
181. Method for making humanized antibodies
      
182. Monoclonal antibody against human telomerase catalytic subunit
      
183. Stable salts of S-adenosyl-l-methionine
      
184. Use of strains of parapoxvirus ovis against organ fibrosis
      
185. Mammalian growth factor-7
      
186. Single chain antibody against mutant p53
      
187. Therapeutic inhibitor of vascular smooth muscle cells
      
188. Mutant having uracil phosphoribosyl transferase activity
      
189. Anti-.alpha.v.beta.3 recombinant human antibodies, nucleic acids encoding same
      
190. FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
      
191. Memory loss treatment formulation
      
192. Monoamine oxidase (MAO) inhibitors and uses thereof
      
193. Vaccine compositions for mucosal delivery
      
194. Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
      
195. Artificial proteoglycans
      
196. Oncogene-induced apoptosis in drug-resistant cells
      
197. Methods for treating cell death diseases and inflammation
      
198. Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
      
199. Acceleration of the rate of digestion of a protein
      
200. Synthetic endogenous cannabinoids analogues and uses thereof
      
201. Methods of using BCL-2 for the therapeutic treatment and prevention of diseases
      
202. Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin
      
203. Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract
      
204. Human thyroid protein ZSIG45
      
205. Method of stimulating an immune response with activated dendritic cells
      
206. Multimeric immunotoxins
      
207. Antioxidant activity in SDG metabolites
      
208. Mixture of primary fatty acids obtained from sugar cane wax
      
209. Devices for the delivery of drugs having antiprogestinic properties
      
210. Topical and oral delivery of arginine to cause beneficial effects
      
211. Therapeutic using a bispecific antibody
      
212. Purposeful movement of human migratory cells away from an agent source
      
213. Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
      
214. Specific pancreatic lipase inhibitors and their applications
      
215. Keratinocyte derived interferon
      
216. Death domain containing receptor-4
      
217. Method and compositions for increasing intestinal absorption of fats
      
218. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
      
219. Method for judging effectiveness of drug having protease inhibitory activity
      
220. Double capsule for the administration of active principles in multiple therapies
     
     
221. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
      
     
222. Method of preventing neuronal death
      
     
223. Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus
      
     
224. Product and method reduce stress induced immune suppression
      
     
225. Insulin-like growth factor agonist molecules
      
     
226. Medicament comprising HGF gene
      
     
227. Regulation of cytokine synthesis and release
      
     
228. Topical and oral delivery of arginine to cause beneficial effects

1. Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region
    
2. Target for regulating multiple sclerosis
    
3. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
    
4. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
    
5. Cladribine regimen for treating multiple sclerosis
    
6. DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus
    
7. Therapeutic peptides for demyelinating conditions
    
8. LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
    
9. Osteopontin-related compositions and methods
    
10. Use of treosulfan and derivatives thereof for treating multiple sclerosis
     
11. Method for diagnosing a person having multiple sclerosis
     
12. Methods and reagents for the treatment of multiple sclerosis
     
13. Treatment of demyelinating autoimmune disease with ordered peptides
     
14. Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
     
15. Use Of Regularly Scheduled High Dose Intravenous Methotrexate Therapy, With Interim Administration Of Immunomodulatory Agents, To Treat Multiple Sclerosis And Other Diseases Of The Central Nervous System
     
16. Methods and reagents for the treatment of multiple sclerosis
     
17. Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
     
18. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
     
19. Methods and treatment of multiple sclerosis
     
20. Methods for treating multiple sclerosis employing desmethylselegiline
     
21. Method of treating multiple sclerosis
     
22. Inhibiting MOG-antibody binding
     
23. Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tyrptophan and possibly a vitamin B12 compound
     
24. Treatment of demyelinating autoimmune disease with ordered peptides
     
25. Treatment of fatigue, head injury and stroke
     
26. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
    
    
27. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
    
    
28. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
     
    
29. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
     
    
30. Method for treatment of multiple sclerosis and related disease states
     
    
31. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
     
    
32. Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

1. Vaccine against mumps containing a jeryl-lynn virus strain

1. Composition for maintaining androgen and androgen-like uptake potential by cells
    
2. Compositions and methods for modulating muscle cell and tissue contractility
    
3. Delivery of muscle relaxants through an inhalation route
    
4. Therapy for injured muscles
    
5. Protein specific for cardiac and skeletal muscle
    
6. Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
    
7. Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
    
8. Method for treating muscle spasm with botulinum toxin type B
    
9. Delivery of muscle relaxants through an inhalation route
    
10. Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
     
11. Topically applied creatine containing composition
     
12. Use of insulin-like growth factor-I in muscle
     
13. Method for treating a cholinergic influenced sweat gland
     
14. Treatment of bruxism
     
15. Method for improving muscle control and muscle tone and improving sensory integration
     
16. Pharmaceutical composition for muscular anabolism

1. Methods of treating musculodegenerative disease with an antibody that binds growth differentiation factor-8
    
2. Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation
    
3. Gene responsible for stargardt-like dominant macular dystrophy
    
4. Medicament for treatment of Duchenne muscular dystrophy

1. In vitro model of latent mycobacterial infection
    
2. Identification of specific differentially expressed antigens
    
3. Fused protein, gene therefor, recombinant vector, recombinant virus, and its use
    
4. Process for producing a recombinant protein in a mycobacterium host plasmid pJAM2
    
5. Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
    
6. Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
    
7. Vaccine against mycobacterial infections

1. Molecular determinants of myeloma bone disease and uses thereof
    
2. Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
    
3. Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
    
4. Treatment of human multiple myeloma by curcumin
    
5. Depletion method of blood plasma ascorbate
    
6. IL1-.beta.: a new target for myeloma therapy
    
7. Compounds and methods for modulating cell-adhesion mediated drug resistance
    
8. Medicinal compositions for treating osseous lesion in multiple myeloma
    
9. Reshaped human anti-HM 1.24 antibody
    
10. Peptides binding to bone marrow stromal cell antigen

1. H-FABP as early predictor of myocardial infarction
    
2. Mycobacterial antigens expressed during latency
    
3. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
    
4. Protection of cardiac myocardium
    
5. PRP composition and minimally invasive method for treating myocardial infarction
    
6. Growth factor therapy mobilization of stem cells into the peripheral blood
    
7. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
    
8. Use of moxonidine for postmyocardial infarction treatment
    
9. Method and system for myocardial infarction repair
    
10. Method for determining susceptibility to heart disease by screening polymorphisms in the vitamin D receptor gene
     
11. Composition for the treatment and prevention of endothelial dysfunction
     
12. Method for the prevention of apoptosis

1. Nerve regeneration employing keratin biomaterials
    
2. Use of il6r/il6 chimera in nerve cell regeneration
    
3. Use of pleiotrophin to promote neurogeneration
    
4. Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
    
5. Morphogen-induced nerve regeneration and repair
    
6. Regeneration and repair of neural tissue using postpartum-derived cells
    
7. Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
    
8. Poly-Glu,Tyr for neuroprotective therapy
    
9. Methods and compositions for nerve regeneration
    
10. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
     
11. Multipotent neural stem cell compositions
     
12. Methods for modulating the axonal outgrowth of central nervous system neurons
     
13. SPRR1A and axonal regeneration
     
14. Screening and therapeutic methods relating to neurogenesis
     
15. Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation
     
16. Methods for identifying an analog that promotes nerve regeneration
     
17. Method of generating neurons from stem cells and medium for culturing stem cells
     
18. Methods of producing neurons
     
19. Method for regulating neuron development and maintenance
     
20. Methods for modulation of the effects of aging on the primate brain
     
21. Nitric oxide donors for inducing neurogenesis
     
22. Differentiation of whole bone marrow
     
23. Multipotent neural stem cell cDNA libraries
     
24. Methods for identifying inhibitors of neuronal degeneration
     
25. Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
     
26. Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
     
27. Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
     
28. Neurogenesis inducing genes
     
29. Proteins related to neuronal regeneration and uses thereof
     
30. Induced regeneration and repair of damaged neurons and nerve axon myelin
     
31. Production of gabaergic cells
     
32. Methods of inducing nervous tissue regeneration
     
33. Use of prosaposin and peptides obtained therefrom for treatment of neural degeneration
     
34. Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF
     
35. Promoters of neural regeneration

1. Biomarker specific to brain/nerve or specific to neuronal differentiation
    
2. Method and mixture for nerve root repair
    
3. Methods of treating inflammation in neuronal tissue
    
4. Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
    
5. Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
    
6. Treatment of injury to the brain by inhibition of acid sensing ion channels
    
7. Treatment of rett syndrome
    
8. Method of preventing and treating brain infarction
    
9. Neural precursor cells, method for the production and use thereof in neural defect therapy
    
10. TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
     
11. Administration of growth factors for the treatment of CNS disorders
     
12. Methods for identifying factors that control the folding of amyloid proteins of diverse origin
     
13. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
     
14. Antibody to BACE455, an alternative splice variant of the human beta-secretase
     
15. Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
     
16. Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors
     
17. Method for transdifferentiating mesenchymal stem cells into neuronal cells
     
18. Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
     
19. Spatial evolution of neural activity
     
20. Method of attenuating neurogenic bruise formation
     
21. Use of TGF beta superfamily antagonists to make dopaminergic neurons from embryonic stem cells
     
22. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
     
23. Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow
     
24. Therapy for cerebral vasospasm
     
25. Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
     
26. Gene functionally related to dyslexia
     
27. Human neuronal attachment factor-1 antibodies
     
28. Methods for the treatment of a traumatic central nervous system injury
     
29. Treatments employing neuronal exocytosis-inhibiting peptides
     
30. Nogo receptor antagonists
     
31. Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system
     
32. Use of ADNF polypeptides for treating peripheral neurotoxicity
     
33. EGFR inhibitors promote axon regeneration
     
34. Glutathione based delivery system
     
35. Polymer conjugates of mutated neublastin
     
36. Proteoglycan degrading mutants for the treatment of CNS
     
37. Method of treating brain tissue damages
     
38. Cells and methods for estimation of effects on neurological dysfunction
     
39. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
     
40. Neural proteins as biomarkers for traumatic brain injury
     
41. Methods for modulating the axonal outgrowth of central nervous system neurons
     
42. SPRR1A and axonal regeneration
     
43. Method and composition for inhibiting reperfusion injury in the brain
     
44. Rapid assays for neurotransmitter transporters
     
45. Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage
     
46. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
     
47. Method of identifying modulators of nogo-functions
     
48. Treatment of brain damage
     
49. Use of osteopontin for the treatment and/or prevention of neurologic diseases
     
50. Methods of preventing or treating brain ischemia or brain injury
     
51. Method of treatment for spinal cord injury
     
52. Methods of producing neurons
     
53. (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
     
54. S(+) desmethylselegiline and its use to treat narcolepsy
     
55. Nitric oxide donors for inducing neurogenesis
     
56. Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
     
57. Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry
     
58. Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
     
59. Human methionine synthase reductase: cloning, and methods for evaluating risk of, preventing, or treating neural tube defects, cardiovascular disease, cancer, and down's syndrome
     
60. Spinal muscular atrophy diagnostic methods
     
61. Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
     
62. Method for modulating nerve cell function
     
63. Method for administering a cytokine to the central nervous system and the lymphatic system
     
64. Schwann cells originating in myeloid interstitial cells
     
65. Composition and method for treating impaired or deteriorating neurological function
     
66. Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
     
67. Methods for screening compounds active on neurons
     
68. Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
     
69. Methods for modulating brain damage
     
70. Neurogenic compositions and methods
     
71. Monoclonal antibodies to Sarcocystis neurona and uses therefor
     
72. Methods for treating neurological injuries and disorders
     
73. Brain, spinal, and nerve injury treatment
     
74. Composition and method for potentiating drugs
     
75. Replication incompetent herpes viruses for use in gene therapy
     
76. Methods for storing neural cells
     
77. Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
     
78. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
     
79. Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
     
80. Method and compositions for treating diseases mediated by transglutaminase activity
     
81. Cell expansion system for use in neural transplantation
     
82. Proteins related to neuronal regeneration and uses thereof
     
83. Immortalized human microglia cell line
     
84. Induced regeneration and repair of damaged neurons and nerve axon myelin
     
85. Models of prion disease
     
86. Immunological detection of prions
     
87. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain
     
88. Method for inducing growth and enhancing survival of nervous tissue
     
89. Mutant herpes simplex viruses and uses thereof
     
90. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
     
91. Treatment of neurological disease
     
92. Methods for therapy of neurodegenerative disease of the brain
     
93. Composition and treatment method for brain and spinal cord injuries
     
94. Diagnosis of tauopathies
     
95. Method and pharmaceutical composition for prevention and treatment of brain damage
     
96. Therapeutic uses for mesenchymal stromal cells
     
97. Method of diagnosing ischemic stroke via UCP-2 detection
     
98. Method of targeting pharmaceuticals to motor neurons
     
99. Method for treating diseases of fungal, yeast, and prion protein etiology
     
100. Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
      
101. Adenoviral-vector-mediated gene transfer into medullary motor neurons
      
102. Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
      
103. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
      
104. Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
      
105. Production of gabaergic cells
      
106. Prevention and treatment of amyloid-associated disorders
      
107. Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
      
108. Polyamine treatment of neurological disorders
      
109. Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
      
110. Method of stable integration of DNA into neurons
      
111. Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF
      
112. Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
      
113. Chimeric toxins
      
114. Methods for using elk-L to enhance neuronal survival
      
115. Immunological agents specific for prion protein (PRP)
      
116. Using glutathiane to protect neurons from injury
      
117. Human metabotropic glutamate receptor 7 subtypes
      
118. Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions
      
119. Nerve regeneration
      
120. Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
      
121. Pharmacotherapeutic process and composition for central nervous system disorders
      
122. Laser inactivation of inhibitory molecules in central nervous system myelin
      
123. Facilitation of repair of neural injury with CM101/GBS toxin
      
124. Method for aiding cerebral recovery following neurodegeneration
      
125. Method for increasing the concentration of ascorbic acid in brain tissue of a subject
      
126. Method of promoting synthesis of nerve growth factor
     
     
127. ARPE-19 as a platform cell line for encapsulated cell-based delivery
     
     
128. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
     
     
129. Semaphorin-specific antibodies
     
     
130. Method for administering fibroblast growth factor to the brain 
     
     
131. Method of preventing neuronal death
      
     
132. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
      
     
133. Method for improving delivery of tyrosine supplementation
      
     
134. Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
      
     
135. Use of kinase inhibitors for treating neurodegenerative diseases
      
     
136. Method for generating dopaminergic cells derived from neural precursors
      
     
137. Protection against traumatic brain injury
      
     
138. Method for determining the prognosis of a patient with a neurological disease
      
     
139. Composition and method for repairing neurological tissue
      
     
140. Methods for treating neuropsychiatric disorders
      
     
141. Method for increasing the concentration of ascorbic acid in brain tissues of a subject
      
     
142. Method of using hedgehog polypeptides to regulate neuronal cell growth
      
     
143. Method for administering neurologic agents to the brain
      
     
144. Non-transgenic rodent model of alzheimer's disease

1. Method for preventing or treating neuropathic pain
    
2. Methods and compositions for modulating and detecting wisp activity
    
3. Application of topical anesthetics for modulation of neurogenic tremor
    
4. Methods of treating musculodegenerative disease with an antibody that binds growth differentiation factor-8
    
5. Leucine-based motif and Clostridial neurotoxins
    
6. Neurotransmission disorders
    
7. Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry
    
8. Sodium channel in dorsal root ganglia
    
9. Method for in vitro propagation of the agent responsible for transmissible spongiform encephalopathies
    
10. Bioactive spinal implant material and method of manufacture thereof
     
11. Leucine-based motif and clostridial neurotoxins
     
12. Method for treating essential tremor with botulinum toxin type B
     
13. Method for treating muscle spasm with botulinum toxin type B
     
14. Proteins within the type E botulinum neurotoxin complex
     
15. Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF
     
16. Biodegradable botulinum toxin implant
     
17. Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
     
18. Method for increasing the bioavailability of metaxalone
    
    
19. Use for pain management
    
    
20. Biodegradable neurotoxin implant
    
    
21. Method for treating dystonia with botulinum toxin types C to G
     
    
22. Botulinum toxin implant

1. Pharmaceutical composition for treating dementia comprising ShRNA inhibiting S100a9 expression
    
2. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
    
3. Method for the diagnosis of schizophrenia
    
4. Prion inhibition
    
5. Diagnosis of tauopathies
    
6. Method of treating peripheral neuropathy
    
7. Antibody to human enzymes of the metalloprotease family
    
8. Botulinum toxin therapy for neuropsychiatric disorders
    
9. Methods and compositions for treating vascular dementia
    
10. Skin test for schizophrenia
     
11. Methods for screening GABA-modulatory compounds for specified pharmacological activities
     
12. Human dopamine receptor and its uses
    
 
13. Neural transplantation using pluripotent neuroepithelial cells
     
14. Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
     
15. Cytokine antagonists for neurological and neuropsychiatric disorders
     
16. Treatment of neurotic disorders
     
17. Emu-based compositions for mental well-being and method of use
     
18. Therapeutic treatments for neuropsychiatric disorders
     
19. Methods for selecting a therapy for a subject suffering from schizophrenia
     
20. Gene and methods for diagnosing neuropsychiatric disorders and treating such disorders
     
21. Method of screening for non-steroidal neuropsychiatric agents
     
22. Composition comprising a tramadol material and an anticonvulsant drug
     
23. Percutaneously applicable preparation and suppository containing an antidementia medicament
     
24. Methods for improving brain function using leptin or analogs thereof
     
25. Nutritional system for nervous system disorders
    
    
26. Treatments for nervous disorders
    
    
27. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders